SuppreMol looks for partner as 'long-lasting' ITP candidate shows clinical promise
This article was originally published in Scrip
Executive Summary
Interim results from SuppreMol's Phase Ib/IIa trial of SM101 to treat primary immune thrombocytopenia (ITP) have provided encouraging efficacy data, prompting the German company to start looking for a pharma partner to develop the drug candidate "in further indications such as rheumatoid arthritis (RA) or multiple sclerosis (MS) or/and support the ongoing programme, which includes a Phase IIa trial in systemic lupus erythematosus (SLE) started last year, with additional funding", CEO Professor Peter Buckel told Scrip.